144 related articles for article (PubMed ID: 16737745)
1. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.
Chen Y; Jirage D; Caridha D; Kathcart AK; Cortes EA; Dennull RA; Geyer JA; Prigge ST; Waters NC
Mol Biochem Parasitol; 2006 Sep; 149(1):48-57. PubMed ID: 16737745
[TBL] [Abstract][Full Text] [Related]
2. The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus.
Jirage D; Chen Y; Caridha D; O'Neil MT; Eyase F; Witola WH; Mamoun CB; Waters NC
Mol Biochem Parasitol; 2010 Jul; 172(1):9-18. PubMed ID: 20332005
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
4. The Malaria Parasite Cyclin H Homolog PfCyc1 Is Required for Efficient Cytokinesis in Blood-Stage
Robbins JA; Absalon S; Streva VA; Dvorin JD
mBio; 2017 Jun; 8(3):. PubMed ID: 28611247
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
Woodard CL; Keenan SM; Gerena L; Welsh WJ; Geyer JA; Waters NC
Bioorg Med Chem Lett; 2007 Sep; 17(17):4961-6. PubMed ID: 17588749
[TBL] [Abstract][Full Text] [Related]
7. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.
Waters NC; Woodard CL; Prigge ST
Mol Biochem Parasitol; 2000 Mar; 107(1):45-55. PubMed ID: 10717301
[TBL] [Abstract][Full Text] [Related]
8. Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Peng Y; Keenan SM; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):72-80. PubMed ID: 16046158
[TBL] [Abstract][Full Text] [Related]
9. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
11. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Li JL; Robson KJ; Chen JL; Targett GA; Baker DA
Eur J Biochem; 1996 Nov; 241(3):805-13. PubMed ID: 8944769
[TBL] [Abstract][Full Text] [Related]
12. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue.
Le Roch K; Sestier C; Dorin D; Waters N; Kappes B; Chakrabarti D; Meijer L; Doerig C
J Biol Chem; 2000 Mar; 275(12):8952-8. PubMed ID: 10722743
[TBL] [Abstract][Full Text] [Related]
13. A genomic perspective of protein kinases in Plasmodium falciparum.
Anamika ; Srinivasan N; Krupa A
Proteins; 2005 Jan; 58(1):180-9. PubMed ID: 15515182
[TBL] [Abstract][Full Text] [Related]
14. Cyclin H is targeted to the nucleus by C-terminal nuclear localization sequences.
Krempler A; Kartarius S; Günther J; Montenarh M
Cell Mol Life Sci; 2005 Jun; 62(12):1379-87. PubMed ID: 15971111
[TBL] [Abstract][Full Text] [Related]
15. Raf kinase inhibitor protein affects activity of Plasmodium falciparum calcium-dependent protein kinase 1.
Kugelstadt D; Winter D; Plückhahn K; Lehmann WD; Kappes B
Mol Biochem Parasitol; 2007 Jan; 151(1):111-7. PubMed ID: 17123645
[TBL] [Abstract][Full Text] [Related]
16. Exploring the role of putative active site amino acids and pro-region motif of recombinant falcipain-2: a principal hemoglobinase of Plasmodium falciparum.
Kumar A; Dasaradhi PV; Chauhan VS; Malhotra P
Biochem Biophys Res Commun; 2004 Apr; 317(1):38-45. PubMed ID: 15047145
[TBL] [Abstract][Full Text] [Related]
17. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Woodard CL; Li Z; Kathcart AK; Terrell J; Gerena L; Lopez-Sanchez M; Kyle DE; Bhattacharjee AK; Nichols DA; Ellis W; Prigge ST; Geyer JA; Waters NC
J Med Chem; 2003 Aug; 46(18):3877-82. PubMed ID: 12930149
[TBL] [Abstract][Full Text] [Related]
18. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control.
Oelgeschläger T
J Cell Physiol; 2002 Feb; 190(2):160-9. PubMed ID: 11807820
[TBL] [Abstract][Full Text] [Related]
19. The Medicago CDKC;1-CYCLINT;1 kinase complex phosphorylates the carboxy-terminal domain of RNA polymerase II and promotes transcription.
Fülöp K; Pettkó-Szandtner A; Magyar Z; Miskolczi P; Kondorosi E; Dudits D; Bakó L
Plant J; 2005 Jun; 42(6):810-20. PubMed ID: 15941395
[TBL] [Abstract][Full Text] [Related]
20. A novel ERK-like, CRK-like protein kinase that modulates growth in Trypanosoma brucei via an autoregulatory C-terminal extension.
Ellis J; Sarkar M; Hendriks E; Matthews K
Mol Microbiol; 2004 Sep; 53(5):1487-99. PubMed ID: 15387824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
